You can buy or sell CLSD and other stocks, options, ETFs, and crypto commission-free!
Clearside Biomedical, Inc. Common Stock, also called Clearside Biomedical, is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Read More Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
52 Week High
52 Week Low
Seeking AlphaMar 12
Clearside Biomedical, Inc. (CLSD) CEO Daniel White on Q4 2018 Results - Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2018 Earnings Conference Call March 12, 2019 5:00 PM ET Company Participants Jenny Kobin - Investor Relations Daniel White - President & Chief Executive Officer Thomas Ciulla - Chief Medical Officer Brion Raymond - Chief Commercial Officer Charlie Deignan - CFO Conference Call Participants Tessa Romero - JPMorgan Nick Rubino - Stifel Liana Moussatos - Wedbush Securities Tian Sun - Needham François Brisebois - Laidlaw Operator Good day, ladies and gen...
Associated PressMar 12
Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. - Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform -- XIPERE™ NDA Accepted and On Track for October 19, 2019 PDUFA Date -- Management to Host Webcast and Conference Call Today at 5:00 PM ET - ...
Stock Price, News, & Analysis for Clearside Biomedical
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vas...
-$0.57 per share
-$0.68 per share